http://www.futuremedicine.com/doi/pdf/10.2217/pmt-2016-0068
Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study
Paul D Gavin*mce-anchor,1mce-anchor, Lee S Simonmce-anchor2mce-anchor, Thomas Schlagheckmce-anchor3mce-anchor, Alisha J Smithmce-anchor1mce-anchor & Sepehr Shakibmce-anchor4mce-anchor
*Author for correspondence: [email protected]
Aim: To characterize the pharmacokinetic profile and evaluate the safety and tolerability of a transdermal oxycodone patch containing tocopheryl phosphate mixture (TPM). Patients & methods: Eleven healthy subjects received a single application of three TPM/oxycodone patches applied to the torso for 72 h. Results: Oxycodone was detected 8.0 ± 2.7-h postpatch administration, reaching a mean maximum plasma concentration of 3.41 ± 1.34 ng/ml at 49.3 ± 21.2 h. The safety profile was consistent with the application method and known side-effect profile of oxycodone and naltrexone. No treatment-limiting skin irritation was observed. Conclusion: A 3-day application of the TPM/oxycodone patch demonstrated an acceptable safety profile and was well tolerated by healthy subjects, with limited dermal irritation following application.
http://www.futuremedicine.com/doi/pdf/10.2217/pmt-2016-0067
Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial
Paul D Gavin*mce-anchor,1mce-anchor, Louise Trempermce-anchor1mce-anchor, Alisha Smithmce-anchor1mce-anchor, Gemma Williamsmce-anchor2mce-anchor & Charles Brookermce-anchor3mce-anchor
*Author for correspondence: [email protected]
Aim: To evaluate the efficacy, systemic exposure, safety and tolerability of a transdermal oxycodone patch containing tocopheryl phosphate mixture (TPM) in patients with postherpetic neuralgia (PHN). Patients & methods: The study was a Phase IIa, multicenter, randomized, double-blind, vehicle-controlled crossover study. Results: While the TPM/oxycodone patch did not significantly improve ‘average’ Numeric Pain Rating Scale scores versus vehicle patch, patients reporting high levels of paresthesia (n = 9) showed a trend toward improved pain reduction. The TPM/oxycodone patch resulted in a low systemic exposure to oxycodone and was well tolerated. Conclusion: The TPM/oxycodone patch delivered oxycodone to the site of perceived pain in subjects suffering from PHN, but did not provide analgesia for the broad PHN indication.
- Forums
- ASX - By Stock
- AVE
- Research Articles
Research Articles, page-2
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
-0.001(16.7%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $15 | 5.842K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
50 | 88227619 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 60194641 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
50 | 88227619 | 0.002 |
21 | 68595508 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 60194641 | 22 |
0.004 | 16588374 | 14 |
0.005 | 21833333 | 9 |
0.006 | 19255067 | 9 |
0.007 | 5722471 | 6 |
Last trade - 14.52pm 22/08/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online